This WHO technical consultation report from December 2020 focuses on the preferred products for drugs used in malaria prevention and treatment. It outlines the process for developing Preferred Product Characteristics (PPCs) to guide product developers, regulatory agencies, and funders in aligning with WHO's research and development priorities. The report emphasizes the importance of PPCs in addressing public health needs by setting strategic health goals for new malaria drugs, considering efficacy, safety, and cost-effectiveness. The document also discusses the challenges of developing new malaria drugs and vaccines due to the complexity of the malaria parasite and highlights the need for collaboration between WHO, regulatory authorities, and public health officials to ensure effective malaria control strategies.